Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,699,492

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,699,492 protect, and when does it expire?

Patent 6,699,492 protects BESIVANCE and is included in one NDA.

This patent has thirty patent family members in sixteen countries.

Summary for Patent: 6,699,492
Title: Quinolone carboxylic acid compositions and related methods of treatment
Abstract:The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
Inventor(s): Roy; Samir (San Ramon, CA), Chandrasekaran; Santosh Kumar (Moraga, CA), Imamori; Katsumi (Chiba, JP), Asaoka; Takemitsu (Chiba, JP), Shibata; Akihiro (Chiba, JP), Takahashi; Masami (Tokyo, JP), Bowman; Lyle M. (Pleasanton, CA)
Assignee: InSite Vision Incorporated (Alameda, CA) SSP Co., Ltd. (Tokyo, JP)
Application Number:10/126,513
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Delivery;

Drugs Protected by US Patent 6,699,492

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes   Start Trial   Start Trial Y METHOD OF TREATING OCULAR BACTERIAL INFECTIONS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,699,492

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 296093   Start Trial
Australia 2002322002   Start Trial
Australia 3920300   Start Trial
Australia 772228   Start Trial
Canada 2368637   Start Trial
Canada 2445408   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.